Member Info for marik

Its looks like revenues will continue for a long time to come

Some of that could be for other companies, but we are just days away before the Gov make an announcement. Could a very exciting month.

With a potential £12Bn per year contract on the very near horizon, there could be a big party.

The Innova £1Bn per month is up for renewal. This could become substantial revenue over the coming years for home grown tests. Avacta with the best test currently developed is likely to benefit.

https://www.independent.co.uk/independentpremium/covid-rapid-test-innova-latest-b1856023.html

There could be a rapid rise in price over the coming week.

The Innova £1Bn per month is up for renewal. This could become substantial revenue over the coming years for home grown tests. Avacta with the best test currently developed is likely to benefit.

This needs Avacta

I'm predicting a large chunk of the antibody market to be disrupted. A share of a $100Bn market will put Avacta strongly on the map for many years to come.

Agree, that is the bottom line. The best test will have the longest lifespan culminating in a longer revenue runway as others reduce over time.

Wiggy, the RNS pointed to a UK based sales already penned post CE approval. That explains why the price was blue.

Could there be an intraday RNS?

BearBullDozer, that's not the kind of high you will score from Avacta.

This is a an all time (share price) high party.

Where's Hoochy?

I could do with straight to £10 - this week will be a cracker.

Many are surprised the upward share price movement, but the recent RNS was very positive between the lines.

It stated that, "...the Company has continued its discussions with distributors and customers for the AffiDX® antigen test and does not anticipate that the error will cause a delay to first commercial sales of the product."

Implying that there is a UK buyer lined up, as the error was in the UK MHRA submission and any delay would be for the UK. To confirm they've also stated that the European application is separate but being carried out in parallel.

It suggests to me that at least two sales are on the ready and in the UK, it will be with the UK Gov. It would explain the rise in share price as the penny drops.

It can be walked down to fulfil an order - which is in line with the positive news of a Substantial Dividend.

"Someone who is enjoying themselves a little too much"

Could this be the famous missing line from A Little Less Conversation by Elvis?

As mentioned by a recent RNS, that a credible buyer wanting significantly all the assets. In due course, a circular would be published by the Company before "a general meeting".

Are there any views as to when the circular will be released and the meeting will be held?

I'm assuming that both of these will be fairly soon, due to the way the company is developing and the nature of the RNS.

I recently read that another lateral flow test manufacturer in the UK was under a right of first refusal by the UK Gov.

I'm not keen on Avacta selling to the UK Gov and would have preferred international sales. However, I speculate; if Avacta have signed a right of first refusal clause, then the European sales are dependent on the UK Gov confirming how many LFT they order from Avacta.

As the RNS pluralised the sale(s), I would assume that Avacta have at least two contracts drafted and one of them is in the UK.

My assumption is that the sales figures will be big.

Also, as the European application was a separate event, the UK application was purely for a UK costumer.

I'm assuming it's the UK Gov.

The RNS confirms that form submission in the UK was delayed, but goes on to say that despite this, post discussion with distributors and customers, the "...first commercial sales of the product", will continue on schedule.

To me this implies that the customer and distributor(s) are in the UK.

GLA